<!DOCTYPE html>
<html lang="ja">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Pharma Daily Brief | PiercePharma 朝刊</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Noto+Sans+JP:wght@400;500;600;700&family=IBM+Plex+Sans:wght@400;500;600&display=swap" rel="stylesheet">
  <style>
    :root {
      --bg-main: #0f1419;
      --bg-card: #1a2332;
      --bg-card-hover: #232f42;
      --text-primary: #e8edf4;
      --text-secondary: #94a3b8;
      --text-muted: #64748b;
      --accent-pipeline: #38bdf8;
      --accent-regulatory: #fb923c;
      --accent-deals: #4ade80;
      --accent-earnings: #a78bfa;
      --border: #2d3a4f;
      --link: #7dd3fc;
      --link-hover: #bae6fd;
    }
    * { box-sizing: border-box; margin: 0; padding: 0; }
    body { font-family: 'IBM Plex Sans', 'Noto Sans JP', sans-serif; background: var(--bg-main); color: var(--text-primary); line-height: 1.6; min-height: 100vh; padding: 24px 16px; }
    .container { max-width: 720px; margin: 0 auto; }
    .header { margin-bottom: 32px; padding-bottom: 20px; border-bottom: 1px solid var(--border); }
    .header h1 { font-size: 1.5rem; font-weight: 700; letter-spacing: -0.02em; }
    .header .date { font-size: 0.875rem; color: var(--text-muted); margin-top: 4px; font-weight: 500; }
    .header .subtitle { font-size: 0.8125rem; color: var(--text-secondary); margin-top: 8px; }
    .header .scope { font-size: 0.75rem; color: var(--text-muted); margin-top: 12px; padding: 10px 12px; background: var(--bg-card); border-radius: 6px; border: 1px solid var(--border); line-height: 1.5; }
    .header .scope strong { color: var(--text-secondary); }
    .category-section { margin-bottom: 28px; }
    .category-header { display: flex; align-items: center; gap: 8px; margin-bottom: 12px; font-size: 0.8125rem; font-weight: 600; text-transform: uppercase; letter-spacing: 0.05em; }
    .category-header .badge { width: 8px; height: 8px; border-radius: 50%; }
    .category-pipeline .badge { background: var(--accent-pipeline); } .category-pipeline .category-header { color: var(--accent-pipeline); }
    .category-regulatory .badge { background: var(--accent-regulatory); } .category-regulatory .category-header { color: var(--accent-regulatory); }
    .category-deals .badge { background: var(--accent-deals); } .category-deals .category-header { color: var(--accent-deals); }
    .category-earnings .badge { background: var(--accent-earnings); } .category-earnings .category-header { color: var(--accent-earnings); }
    .article-card { background: var(--bg-card); border: 1px solid var(--border); border-left: 3px solid; border-radius: 8px; padding: 16px; margin-bottom: 12px; transition: background 0.2s; }
    .article-card:hover { background: var(--bg-card-hover); }
    .article-card.pipeline { border-left-color: var(--accent-pipeline); }
    .article-card.regulatory { border-left-color: var(--accent-regulatory); }
    .article-card.deals { border-left-color: var(--accent-deals); }
    .article-card.earnings { border-left-color: var(--accent-earnings); }
    .article-card .title { font-size: 1rem; font-weight: 600; margin-bottom: 8px; line-height: 1.4; }
    .article-card .title a { color: var(--text-primary); text-decoration: none; transition: color 0.2s; }
    .article-card .title a:hover { color: var(--link-hover); }
    .article-card .summary { font-size: 0.875rem; color: var(--text-secondary); margin-bottom: 10px; line-height: 1.5; }
    .article-card .meta { display: flex; flex-wrap: wrap; gap: 12px; font-size: 0.75rem; color: var(--text-muted); }
    .article-card .meta span { display: inline-flex; align-items: center; gap: 4px; }
    .article-card .link-wrap { margin-top: 10px; }
    .article-card .link-wrap a { font-size: 0.8125rem; color: var(--link); text-decoration: none; transition: color 0.2s; }
    .article-card .link-wrap a:hover { color: var(--link-hover); text-decoration: underline; }
    .article-card .link-wrap a::after { content: '→'; }
    .importance { display: inline-flex; gap: 2px; }
    .importance .star { color: var(--accent-regulatory); font-size: 0.7rem; }
    .importance .star.empty { color: var(--text-muted); opacity: 0.5; }
    .article-card .meta .region { font-size: 0.7rem; padding: 2px 6px; border-radius: 4px; font-weight: 500; }
    .region-us { background: rgba(56,189,248,0.2); color: var(--accent-pipeline); }
    .region-europe { background: rgba(251,146,60,0.2); color: var(--accent-regulatory); }
    .region-china { background: rgba(74,222,128,0.2); color: var(--accent-deals); }
    @media (max-width: 480px) { body { padding: 16px 12px; } .header h1 { font-size: 1.25rem; } .article-card { padding: 14px; } }
  </style>
</head>
<body>
  <div class="container">
    <header class="header">
      <h1>Pharma Daily Brief</h1>
      <div class="date">2026年02月23日（月）</div>
      <div class="subtitle">パイプライン・規制・M&A・決算｜医薬・バイオ業界の重要ニュース（毎朝更新）</div>
      <div class="scope">
        <strong>対象地域：</strong>約9割は米国。欧州はノボノルディスク、ブリストルマイヤーズスクイーブ、サノフィ、ロッシュ、バイエルなど大手の重要ニュースを追加。中国は個別企業より<strong>医薬品規制当局の動向</strong>（変化が大きい場合）を掲載。
      </div>
    </header>


    <section class="category-section category-pipeline">
      <h2 class="category-header">
        <span class="badge"></span>
        Pipeline
      </h2>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.biopharmadive.com/spons/all-about-cell-therapy-process-characterization/812719/" target="_blank" rel="noopener">All about cell therapy process characterization</a></h3>
        <p class="summary">Why process characterization is the key to consistent, safe, and scalable cell therapies.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.biopharmadive.com/spons/all-about-cell-therapy-process-characterization/812719/" target="_blank" rel="noopener">BioPharma Dive </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.biopharmadive.com/spons/small-and-mighty-single-domain-antibodies-pack-a-biological-punch/811314/" target="_blank" rel="noopener">Small and mighty: single-domain antibodies pack a biological punch</a></h3>
        <p class="summary">VHH antibodies, they’re not just small, they&#x27;re modular engineering platforms, capable of powerful biological activity. But with great power comes great challenges!</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.biopharmadive.com/spons/small-and-mighty-single-domain-antibodies-pack-a-biological-punch/811314/" target="_blank" rel="noopener">BioPharma Dive </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.biopharmadive.com/news/grails-multi-cancer-early-detection-test-misses-study-goal/812744/" target="_blank" rel="noopener">Grail’s multi-cancer early detection test misses study goal</a></h3>
        <p class="summary">Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with a statistically significant reduction in late-stage cancer diagnoses.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.biopharmadive.com/news/grails-multi-cancer-early-detection-test-misses-study-goal/812744/" target="_blank" rel="noopener">BioPharma Dive </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.biopharmadive.com/news/supreme-court-invalidates-trump-tariffs-based-on-emergency-powers/812723/" target="_blank" rel="noopener">Supreme Court invalidates Trump tariffs based on emergency powers</a></h3>
        <p class="summary">In a 6-3 decision, the court rejected President Trump&#x27;s claim that a 1977 law gave him the authority to impose broad tariffs globally.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.biopharmadive.com/news/supreme-court-invalidates-trump-tariffs-based-on-emergency-powers/812723/" target="_blank" rel="noopener">BioPharma Dive </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.biopharmadive.com/news/roche-giredestrant-serd-fda-approval-decision-breast-cancer/812695/" target="_blank" rel="noopener">Roche gets FDA decision date on closely watched breast cancer drug</a></h3>
        <p class="summary">The agency could by late December approve a therapy that Roche sees as potentially becoming a new treatment standard for certain breast tumors.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.biopharmadive.com/news/roche-giredestrant-serd-fda-approval-decision-breast-cancer/812695/" target="_blank" rel="noopener">BioPharma Dive </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.biopharmadive.com/news/madrigal-earnings-daiichi-tsai-acimmune-alzheimers-novartis-unnatural/812565/" target="_blank" rel="noopener">Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi</a></h3>
        <p class="summary">Madrigal shares fell 11% despite again topping consensus sales numbers. Elsewhere, Daiichi Sankyo named a new research chief and J&amp;J halted recruitment in an Alzheimer’s trial.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.biopharmadive.com/news/madrigal-earnings-daiichi-tsai-acimmune-alzheimers-novartis-unnatural/812565/" target="_blank" rel="noopener">BioPharma Dive </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.biopharmadive.com/news/ai-biotech-pharma-jobs-layoffs-amazon-nvidia-pharma/812635/" target="_blank" rel="noopener">AI is slashing jobs across industries. Will pharma be next?</a></h3>
        <p class="summary">Despite a wave of AI-fueled layoffs, the pharma and biotech industries could be spared from massive cutbacks for now.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.biopharmadive.com/news/ai-biotech-pharma-jobs-layoffs-amazon-nvidia-pharma/812635/" target="_blank" rel="noopener">BioPharma Dive </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.biopharmadive.com/news/Altesa-biotech-startup-financing-giroir-vapendavir-copd-lung/812566/" target="_blank" rel="noopener">Altesa, run by former Trump official, raises $75M for well-traveled lung drug</a></h3>
        <p class="summary">Led by Brett Giroir and GSK’s ex-chief medical officer, Altesa is advancing a medicine that’s changed hands multiple times and once failed a study in asthma.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.biopharmadive.com/news/Altesa-biotech-startup-financing-giroir-vapendavir-copd-lung/812566/" target="_blank" rel="noopener">BioPharma Dive </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.biopharmadive.com/news/fda-makary-prasad0one-pivotal-trial-nejm/812557/" target="_blank" rel="noopener">FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals</a></h3>
        <p class="summary">In a NEJM article, Commissioner Martin Makary and top deputy Vinay Prasad argued that the new policy should lower development costs and speed development without compromising agency standards.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.biopharmadive.com/news/fda-makary-prasad0one-pivotal-trial-nejm/812557/" target="_blank" rel="noopener">BioPharma Dive </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.biopharmadive.com/news/lilly-deal-csl-100m-license-monoclonal-antibody-targeting-il-6/812455/" target="_blank" rel="noopener">Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6</a></h3>
        <p class="summary">The Australian company will retain rights for an end-stage kidney disease indication currently being tested in a Phase 3 trial while Lilly explores other uses.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.biopharmadive.com/news/lilly-deal-csl-100m-license-monoclonal-antibody-targeting-il-6/812455/" target="_blank" rel="noopener">BioPharma Dive </a></div>
      </article>
    </section>

    <footer style="margin-top: 40px; padding-top: 20px; border-top: 1px solid var(--border); font-size: 0.75rem; color: var(--text-muted);">
      Pharma Daily Brief — PiercePharma 朝刊 | 米国中心・欧州大手・中国規制を含む医薬・バイオ業界の重要ニュース
    </footer>
  </div>
</body>
</html>